Carlos Panizo

3.8k total citations
93 papers, 1.5k citations indexed

About

Carlos Panizo is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Carlos Panizo has authored 93 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Pathology and Forensic Medicine, 36 papers in Genetics and 32 papers in Oncology. Recurrent topics in Carlos Panizo's work include Lymphoma Diagnosis and Treatment (49 papers), Chronic Lymphocytic Leukemia Research (30 papers) and CAR-T cell therapy research (18 papers). Carlos Panizo is often cited by papers focused on Lymphoma Diagnosis and Treatment (49 papers), Chronic Lymphocytic Leukemia Research (30 papers) and CAR-T cell therapy research (18 papers). Carlos Panizo collaborates with scholars based in Spain, United States and United Kingdom. Carlos Panizo's co-authors include Eduardo Rocha, Alberto Órfão, Eva González‐Barca, Juan‐Manuel Sancho, Maurizio Bendandi, Ramón Montes, Ricardo Garcı́a-Muñoz, Francisco Vega, Felipe Prósper and Moses Rodriguez and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Carlos Panizo

90 papers receiving 1.4k citations

Peers

Countries citing papers authored by Carlos Panizo

Since Specialization

Citations

This map shows the geographic impact of Carlos Panizo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carlos Panizo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carlos Panizo more than expected).

Fields of papers citing papers by Carlos Panizo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carlos Panizo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carlos Panizo. The network helps show where Carlos Panizo may publish in the future.

Co-authorship network of co-authors of Carlos Panizo

This figure shows the co-authorship network connecting the top 25 collaborators of Carlos Panizo. A scholar is included among the top collaborators of Carlos Panizo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carlos Panizo. Carlos Panizo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Venetoclax improves CD20 immunotherapy in a mouse model of MYC/BCL2 double-expressor diffuse large B-cell lymphoma 2023 ·Journal for ImmunoTherapy of Cancer ·(unknown), (unknown), (unknown), (unknown), Marién Pascual, Carlos Panizo, Óscar Blanco, Víctor Segura, Francisco J. Novo, Juan García Valero, Patricia Pérez‐Galán, José A. Martínez-Climent, Sergio Roa	5
2	Deep Characterization of Immune Dysfunction in Patients with Multiple Myeloma (MM) and Identification of Cellular Biomarkers for Tailored Vaccination Strategies 2023 ·Blood ·Esperanza Martín‐Sánchez, (unknown), (unknown), (unknown), Aintzane Zabaleta, Catarina Maia, Laura Blanco, (unknown), Carlos Grande, (unknown), (unknown), (unknown), Ernesto Pérez Persona, (unknown), (unknown), Carlos Panizo, Felipe Prósper, Jesús F. San Miguel, Paula Rodríguez‐Otero, Bruno Paiva	0
3	Mini review: Advances and challenges in CAR-T cell therapy: from early chimeric antigen receptors to future frontiers in oncology 2023 ·SHILAP Revista de lepidopterología ·(unknown), María C. Viguria, Carlos Panizo, Juan R. Rodríguez-Madoz, Felipe Prósper	1
4	Maintenance therapy with ex vivo expanded lymphokine‐activated killer cells and rituximab in patients with follicular lymphoma is safe and may delay disease progression 2020 ·British Journal of Haematology ·Ascensión López-Dı́az de Cerio, Ricardo Garcı́a-Muñoz, (unknown), Ángel Panizo, (unknown), Pilar Giraldo, Mercedes Rodrı́guez-Calvillo, Nicolás Martínez‐Calle, Carlos Grande, (unknown), Marcio Andrade‐Campos, Eva Bandrés, Jorge M. Núñez‐Córdoba, Susana Inogés, Carlos Panizo	5
5	Long-term follow-up of a prospective phase 2 clinical trial of extended treatment with rituximab in patients with B cell post-transplant lymphoproliferative disease and validation in real world patients 2020 ·Annals of Hematology ·(unknown), Eva González‐Barca, Francisco Capote, José Gómez‐Codina, Carlos Panizo, Antonio Salar, Juan‐Manuel Sancho, Andrés López, Javier Briones, Andrés Muñoz, Maite Encuentra, Santiago Mercadal, Eva Domingo‐Doménech, Alberto Fernández de Sevilla	8
6	The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma 2019 ·Clinical Cancer Research ·Laura Moreno, Cristina Pérez, Aintzane Zabaleta, Irene Manrique, Diego Alignani, Daniel Ajona, Laura Blanco, Marta Lasa, Patricia Maiso, Idoia Rodríguez, Sonia Gárate, Tomáš Jelı́nek, Víctor Segura, Cristina Moreno, Juana Merino, Paula Rodríguez‐Otero, Carlos Panizo, Felipe Prósper, Jesús F. San Miguel, Bruno Paiva	148
7	Safety of switching from intravenous to subcutaneous rituximab during first‐line treatment of patients with non‐Hodgkin lymphoma: the Spanish population of the MabRella study 2019 ·British Journal of Haematology ·Ricardo Garcı́a-Muñoz, Cristina Quero, Ernesto Pérez Persona, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Carlos Panizo	11
8	Guidelines for diagnosis, prevention and management of central nervous system involvement in diffuse large B-cell lymphoma patients by the Spanish Lymphoma Group (GELTAMO) 2016 ·Haematologica ·Francisco‐Javier Peñalver, Juan‐Manuel Sancho, Adolfo de la Fuente, (unknown), Alejandro Martı́n, Carlos Panizo, (unknown), Antonio Salar, Alberto Órfão	36
9	Follicular lymphoma (FL): Immunological tolerance theory in FL 2016 ·Human Immunology ·Ricardo Garcı́a-Muñoz, Carlos Panizo	2
10	Relationship between respiratory and food allergy and evaluation of preventive measures 2015 ·Allergologia et Immunopathologia ·Francisco Vega, Carlos Panizo, M T Dordal, (unknown), (unknown), Antonio Valero, M C Sánchez, Carmen Rondón, J Montoro, Víctor Matheu, M Lluch‐Bernal, (unknown), B Fernández-Parra, A del Cuvillo, Ignacio Dávila, C. Colás, Paloma Campo, E. Antón, Ana Navarro	9
11	Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial 2014 ·Haematologica ·Javier Briones, Silvana Novelli, José A. García‐Marco, José Francisco Tomás, Teresa Bernal, Carlos Grande, Miguel Canales, António Torres, (unknown), Carlos Panizo, Isidro Jarque, (unknown), Matthew C. Hernandez, Eva González‐Barca, (unknown), D. Caballero, (unknown)	3
12	Rituximab in dermatology 2013 ·Actas Dermo-Sifiliográficas ·Agustı́n España, Enrique Ornilla, Carlos Panizo	6
13	Effect of addition of rituximab to salvage chemotherapy on outcome of patients with diffuse large B-cell lymphoma relapsing after an autologous stem-cell transplantation 2010 ·Annals of Oncology ·(unknown), Alejandro Martı́n, E. Condé, Antonio Pascual, Inmaculada Heras, Rosario Varela, Javier de la Rubia, (unknown), José L. Díez‐Martín, Carlos Panizo, (unknown), María Pascual, (unknown), Eva González‐Barca, Marı́a Dolores Caballero	9
14	Autoimmunity and lymphoma: Is mantle cell lymphoma a mistake of the receptor editing mechanism? 2009 ·Leukemia Research ·Ricardo Garcı́a-Muñoz, Carlos Panizo, Maurizio Bendandi, Luis Llorente	15
15	Efficacy and safety of liposomal cytarabine in lymphoma patients with central nervous system involvement from lymphoma 2009 ·Cancer ·(unknown), Carlos Panizo, (unknown), Guillermo Debén, Alberto Álvarez‐Larrán, Eva González‐Barca, Juan‐Manuel Sancho, María Jesús Peñarrubia, (unknown), José A. García-Vela	27
16	Prolonged idiotypic vaccination against follicular lymphoma 2009 ·Leukemia & lymphoma ·Susana Inogés, Ascensión López-Dı́az de Cerio, Natalia Zabalegui, Elena Soria, Helena Villanueva, Carlos Panizo, Arancha Rodríguez‐Caballero, (unknown), Fernando Pastor, Mercedes Rodrı́guez-Calvillo, Alberto Órfão, Maurizio Bendandi	14
17	Positron Emission Tomography Using 18F-Fluorodeoxyglucose for the Evaluation of Residual Hodgkin's Disease Mediastinal Masses 2004 ·Leukemia & lymphoma ·Carlos Panizo, (unknown), Maurizio Bendandi, Mercedes Rodrı́guez-Calvillo, José Boán, María José García‐Velloso, J Richter, Eduardo Rocha	33
18	Secondary myelodysplastic syndrome after treatment for promyelocytic leukemia 2003 ·Cancer Genetics and Cytogenetics ·Carlos Panizo, Ana Patiño‐García, Ramón Lecumberri, Marı́a José Calasanz, María D. Odero, Maurizio Bendandi, Eduardo Rocha	14
19	Tratamiento de la enfermedad tromboembólica venosa 2000 ·Medicina Clínica ·Eduardo Rocha, Carlos Panizo, Ramón Lecumberri	6
20	Emergence of secondary acute leukemia in a patient treated for osteosarcoma: implications of germline TP53 mutations 1998 ·Medical and Pediatric Oncology ·Carlos Panizo, Ana Patiño‐García, (unknown), J. Rifón, Luis Sierrasesúmaga, Eduardo Rocha	16

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact